Lipocine's NASH therapy candidate achieves meaningful liver fat reduction
Lipocine announced eight-week top-line interim results from an ongoing sixteen-week Liver Fat Imaging study with LPCN 1144. Treatment results showed an absolute mean reduction from baseline of 7.6% liver fat and demonstrated a 38% relative mean liver fat reduction from baseline. January 17, 2019